Bicycle Therapeutics (NASDAQ:BCYC) CEO Sells $21,399.49 in Stock

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) CEO Kevin Lee sold 6,167 shares of the business’s stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $3.47, for a total value of $21,399.49. Following the completion of the sale, the chief executive officer directly owned 597,504 shares in the company, valued at approximately $2,073,338.88. This represents a 1.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Lee also recently made the following trade(s):

• On Monday, October 5th, Kevin Lee sold 1,638 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $3.57, for a total value of $5,847.66.

Bicycle Therapeutics Stock Performance

Shares of NASDAQ BCYC opened at $3.81 on Friday. The stock has a market cap of $266.67 million, a PE ratio of -1.40 and a beta of 1.68. The business has a fifty day moving average of $3.96 and a two-hundred day moving average of $4.29. Bicycle Therapeutics PLC Sponsored ADR has a 52-week low of $3.33 and a 52-week high of $9.16.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Thursday, July 30th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.14). The firm had revenue of $0.63 million during the quarter, compared to the consensus estimate of $4.22 million. Bicycle Therapeutics had a negative return on equity of 33.22% and a negative net margin of 311.11%. Analysts predict that Bicycle Therapeutics PLC Sponsored ADR will post -2.26 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on BCYC. Needham & Company LLC cut their target price on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Friday, October 2nd. Finally, Wall Street Zen upgraded Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Bicycle Therapeutics has a consensus rating of “Hold” and an average target price of $13.86.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of BCYC. Fcpm Iii Services B.V. raised its holdings in Bicycle Therapeutics by 0.5% in the fourth quarter. Fcpm Iii Services B.V. now owns 3,468,430 shares of the company’s stock worth $24,556,000 after purchasing an additional 16,100 shares during the period. Armistice Capital LLC grew its holdings in shares of Bicycle Therapeutics by 8.7% in the 4th quarter. Armistice Capital LLC now owns 3,236,000 shares of the company’s stock valued at $22,911,000 after buying an additional 258,000 shares during the period. Principal Financial Group Inc. increased its position in shares of Bicycle Therapeutics by 2.3% in the 1st quarter. Principal Financial Group Inc. now owns 1,174,625 shares of the company’s stock valued at $5,450,000 after buying an additional 26,353 shares in the last quarter. Renaissance Technologies LLC raised its stake in Bicycle Therapeutics by 72.8% during the 1st quarter. Renaissance Technologies LLC now owns 979,300 shares of the company’s stock worth $4,544,000 after buying an additional 412,700 shares during the period. Finally, Flax Pond Capital LLC acquired a new stake in Bicycle Therapeutics during the 4th quarter worth $1,229,000. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc (NASDAQ:BCYC) is a clinical-stage biotechnology company developing medicines based on its proprietary Bicycle molecule platform. The platform uses short, chemically constrained peptides designed to bind selectively to biological targets, with the goal of combining the tissue penetration and target specificity of small molecules with some of the binding characteristics of larger biologic medicines.

The company is focused primarily on oncology and is developing Bicycle toxin conjugates, immune-cell engaging molecules and other targeted therapeutics.